Product Intro:
Ceftamide-M 1gm is an anticancer injectable therapy that combines Ifosfamide, a powerful alkylating agent, with Mesna, which protects the urinary tract. This dual approach ensures effective cancer treatment while minimizing urological side effects such as hemorrhagic cystitis.
Uses:
Ceftamide-M is used to treat various types of cancers, including:
-
Testicular cancer
-
Soft tissue sarcoma
-
Lymphoma (e.g., Hodgkin and non-Hodgkin lymphoma)
-
Osteosarcoma
-
Lung cancer
-
Cervical and ovarian cancer
Storage Instructions:
-
Store below 25°C in a cool, dry place
-
Protect from light
-
Reconstituted solution should be used immediately or stored as per product guidelines
-
Keep out of reach of children
How it Works (Mechanism of Action):
Ifosfamide works by cross-linking DNA strands, disrupting DNA synthesis and function in cancer cells, which leads to cell death.
Mesna (2-mercaptoethane sulfonate) binds to the toxic metabolites of Ifosfamide in the urinary tract, especially acrolein, preventing damage to the bladder lining.
Side Effects:
Common Side Effects:
-
Nausea and vomiting
-
Hair loss (alopecia)
-
Fatigue
-
Diarrhea
-
Decreased blood counts (anemia, neutropenia)
Severe Side Effects:
-
Hemorrhagic cystitis (prevented by Mesna)
-
Neurotoxicity (confusion, somnolence)
-
Nephrotoxicity
-
Infections due to immunosuppression
-
Pulmonary toxicity
Dosage (Typical Recommended Dose):
-
Dosage depends on the type of cancer, body surface area, and treatment protocol
-
Usually given in cycles with rest periods in between
-
Mesna dose is typically 60-100% of the Ifosfamide dose and administered at specific intervals before and after Ifosfamide
Note: Only to be administered by experienced oncology professionals
Method of Administration:
-
Administered intravenously (IV infusion)
-
Mesna is given via IV or orally before and after Ifosfamide to protect the bladder
-
Adequate hydration is essential during treatment
Precautions:
-
Monitor kidney and liver function during treatment
-
Frequent urinalysis to detect hematuria
-
Avoid in patients with known CNS disorders unless clearly indicated
-
Use with caution in patients with renal or hepatic impairment
-
Not recommended during pregnancy or breastfeeding unless absolutely necessary
Drug Interactions:
-
CYP3A4 inducers/inhibitors can affect Ifosfamide metabolism
-
Increased risk of toxicity when combined with nephrotoxic or neurotoxic agents
-
Interaction with anticoagulants or antiepileptics should be monitored
Allergies:
-
Contraindicated in patients with known hypersensitivity to Ifosfamide, Mesna, or related compounds
-
Signs of allergic reactions may include rash, itching, dizziness, or difficulty breathing
Overdose Information:
-
Symptoms may include severe bone marrow suppression, CNS toxicity, hemorrhagic cystitis
-
Requires immediate medical attention, supportive treatment, and possibly dialysis
-
Hospital monitoring is essential
Missed Dose Instructions:
-
If a dose is missed, consult the oncologist immediately
-
Do not attempt to self-administer or adjust dosage
Additional Notes:
-
Ensure adequate hydration and frequent urination during therapy
-
Routine blood tests are essential to monitor response and manage toxicity
-
Patients should be informed about signs of infection, bleeding, or neurological changes
Product Intro:
Ceftamide-M 1gm is an anticancer injectable therapy that combines Ifosfamide, a powerful alkylating agent, with Mesna, which protects the urinary tract. This dual approach ensures effective cancer treatment while minimizing urological side effects such as hemorrhagic cystitis.
Uses:
Ceftamide-M is used to treat various types of cancers, including:
-
Testicular cancer
-
Soft tissue sarcoma
-
Lymphoma (e.g., Hodgkin and non-Hodgkin lymphoma)
-
Osteosarcoma
-
Lung cancer
-
Cervical and ovarian cancer
Storage Instructions:
-
Store below 25°C in a cool, dry place
-
Protect from light
-
Reconstituted solution should be used immediately or stored as per product guidelines
-
Keep out of reach of children
How it Works (Mechanism of Action):
Ifosfamide works by cross-linking DNA strands, disrupting DNA synthesis and function in cancer cells, which leads to cell death.
Mesna (2-mercaptoethane sulfonate) binds to the toxic metabolites of Ifosfamide in the urinary tract, especially acrolein, preventing damage to the bladder lining.
Side Effects:
Common Side Effects:
-
Nausea and vomiting
-
Hair loss (alopecia)
-
Fatigue
-
Diarrhea
-
Decreased blood counts (anemia, neutropenia)
Severe Side Effects:
-
Hemorrhagic cystitis (prevented by Mesna)
-
Neurotoxicity (confusion, somnolence)
-
Nephrotoxicity
-
Infections due to immunosuppression
-
Pulmonary toxicity
Dosage (Typical Recommended Dose):
-
Dosage depends on the type of cancer, body surface area, and treatment protocol
-
Usually given in cycles with rest periods in between
-
Mesna dose is typically 60-100% of the Ifosfamide dose and administered at specific intervals before and after Ifosfamide
Note: Only to be administered by experienced oncology professionals
Method of Administration:
-
Administered intravenously (IV infusion)
-
Mesna is given via IV or orally before and after Ifosfamide to protect the bladder
-
Adequate hydration is essential during treatment
Precautions:
-
Monitor kidney and liver function during treatment
-
Frequent urinalysis to detect hematuria
-
Avoid in patients with known CNS disorders unless clearly indicated
-
Use with caution in patients with renal or hepatic impairment
-
Not recommended during pregnancy or breastfeeding unless absolutely necessary
Drug Interactions:
-
CYP3A4 inducers/inhibitors can affect Ifosfamide metabolism
-
Increased risk of toxicity when combined with nephrotoxic or neurotoxic agents
-
Interaction with anticoagulants or antiepileptics should be monitored
Allergies:
-
Contraindicated in patients with known hypersensitivity to Ifosfamide, Mesna, or related compounds
-
Signs of allergic reactions may include rash, itching, dizziness, or difficulty breathing
Overdose Information:
-
Symptoms may include severe bone marrow suppression, CNS toxicity, hemorrhagic cystitis
-
Requires immediate medical attention, supportive treatment, and possibly dialysis
-
Hospital monitoring is essential
Missed Dose Instructions:
-
If a dose is missed, consult the oncologist immediately
-
Do not attempt to self-administer or adjust dosage
Additional Notes:
-
Ensure adequate hydration and frequent urination during therapy
-
Routine blood tests are essential to monitor response and manage toxicity
-
Patients should be informed about signs of infection, bleeding, or neurological changes
